Compare NKTX & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKTX | ACOG |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8M | 129.4M |
| IPO Year | 2020 | N/A |
| Metric | NKTX | ACOG |
|---|---|---|
| Price | $2.20 | $5.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $13.25 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 891.9K | 57.7K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $3.75 |
| 52 Week High | $2.74 | $11.54 |
| Indicator | NKTX | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 52.62 | 34.31 |
| Support Level | $2.40 | $5.20 |
| Resistance Level | $2.56 | $5.97 |
| Average True Range (ATR) | 0.14 | 0.44 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 41.04 | 1.28 |
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.